Barry Allen

The University of New South Wales, Australia

Articles in Scholarly Journals [Incomplete List]

  1. The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy
    Physics in Medicine and Biology, vol. 53, no. 2, pp. 319–328, 2008
  2. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer
    Physics in Medicine and Biology, vol. 52, no. 13, pp. L15–L19, 2007
  3. Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
    Applied Radiation and Isotopes, vol. 65, no. 9, pp. 1014–1022, 2007
  4. Addendum to: Basic Immunology of Antibody Targeted Radiotherapy: In Regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8–S14)
    International Journal of Radiation OncologyBiologyPhysics, vol. 68, no. 1, pp. 314–314, 2007
  5. A theoretical model for the production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226
    Applied Radiation and Isotopes, vol. 64, no. 9, pp. 979–988, 2006
  6. Control of prostate cancer spheroid growth using213Bi-labeled multiple targeted a radioimmunoconjugates
    The Prostate, vol. 66, no. 16, pp. 1753–1767, 2006
  7. Internal high linear energy transfer (LET) targeted radiotherapy for cancer
    Physics in Medicine and Biology, vol. 51, no. 13, pp. R327–R341, 2006
  8. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters
    Cancer Letters, vol. 234, no. 2, pp. 176–183, 2006
  9. MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer
    Clinical & Experimental Metastasis, vol. 22, no. 7, pp. 565–573, 2005
  10. Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
    Clinical & Experimental Metastasis, vol. 22, no. 7, pp. 575–586, 2005
  11. Cytotoxicity of breast cancer cells overexpressing HER2/neu by Bi-Herceptin radioimmunoconjugate
    Cancer Letters, vol. 218, no. 2, pp. 181–190, 2005
  12. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction
    Journal of Gastroenterology and Hepatology, vol. 20, no. 2, pp. 256–263, 2005
  13. In Vitro Targeting of NG2 Antigen by 213Bi-9.2.27  -Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells
    Investigative Ophthalmology & Visual Science, vol. 46, no. 12, pp. 4365–4371, 2005
  14. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate
    Cancer Letters, vol. 205, no. 2, pp. 161–171, 2004
  15. Hip girth as a predictor of abdominal adiposity in postmenopausal women*1
    Nutrition, vol. 20, no. 9, pp. 772–777, 2004
  16. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted a-therapy with 213Bi-conjugates1
    International Journal of Radiation OncologyBiologyPhysics, vol. 60, no. 3, pp. 896–908, 2004
  17. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate
    British Journal of Cancer, vol. 91, no. 12, Article ID 6602232, 7 pages, 2004
  18. Targeted alpha therapy for cancer
    Physics in Medicine and Biology, vol. 49, no. 16, pp. 3703–3712, 2004
  19. Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
    British Journal of Cancer, vol. 88, no. 6, Article ID 6600838, 6 pages, 2003
  20. Effects of 20-mg oestradiol implant therapy on bone mineral density, fat distribution and muscle mass in postmenopausal women
    Acta Diabetologica, vol. 40, no. 0, pp. s191–s195, 2003
  21. Body composition of Aboriginal Australian women: comparison with age-matched Caucasians
    Acta Diabetologica, vol. 40, no. 0, pp. s314–s316, 2003
  22. Human uveal melanoma expresses NG2 immunoreactivity
    British Journal of Ophthalmology, vol. 87, no. 5, pp. 629–632, 2003
  23. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
    British Journal of Cancer, vol. 86, no. 7, pp. 1197–1203, 2002
  24. Validity of subjective global assessment as a nutritional marker in end-stage renal disease1
    American Journal of Kidney Diseases, vol. 40, no. 1, pp. 126–132, 2002
  25. Breast Cancer Research and Treatment, vol. 71, no. 2, pp. 149–159, 2002
  26. In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength
    Australasian Radiology, vol. 45, no. 3, pp. 298–304, 2001
  27. In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer
    Colorectal Disease, vol. 3, no. 5, pp. 345–353, 2001
  28. In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: Potential magnetic resonance imaging contrast agents for melanoma
    Journal of Magnetic Resonance Imaging, vol. 14, no. 2, pp. 169–174, 2001
  29. Monte Carlo Modeling of the Effects of Injected Short-, Medium- and Longer-Range Alpha-Particle Emitters on Human Marrow at Various Ages
    Radiation Research, vol. 156, no. 4, p. 413, 2001
  30. Preclinical targeted alpha therapy for subcutaneous melanoma
    Melanoma Research, vol. 11, no. 2, pp. 175–182, 2001
  31. Feasibility study of online high-spatial-resolution MOSFET dosimetry in static and pulsed x-ray radiation fields
    IEEE Transactions on Nuclear Science, vol. 48, no. 6, pp. 2061–2068, 2001
  32. Radioimmunoconjugates for targeted α therapy of malignant melanoma
    Melanoma Research, vol. 10, no. 3, pp. 281–289, 2000
  33. A new silicon detector for microdosimetry applications in proton therapy
    IEEE Transactions on Nuclear Science, vol. 47, no. 4, pp. 1386–1394, 2000
  34. Improved spatial resolution by MOSFET dosimetry of an x-ray microbeam
    Medical Physics, vol. 27, no. 1, p. 239, 2000
  35. The predictive value of body protein for chemotherapy-induced toxicity
    Cancer, vol. 88, no. 4, pp. 796–803, 2000
  36. Comparing different methods of assessing body composition in end-stage renal failure
    Kidney International, vol. 58, no. 1, pp. 408–416, 2000
  37. Physics in Medicine and Biology, vol. 45, no. 1, pp. 59–67, 2000
  38. Breast Cancer Research and Treatment, vol. 57, no. 3, pp. 285–290, 1999
  39. Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer
    Australasian Radiology, vol. 43, no. 4, pp. 480–486, 1999
  40. Performance of Silicon Microdosimetry Detectors in Boron Neutron Capture Therapy
    Radiation Research, vol. 151, no. 3, p. 235, 1999
  41. Fission converter and metal–oxide–semiconductor field effect transistor study of thermal neutron flux distribution in an epithermal neutron therapy beam
    Medical Physics, vol. 26, no. 9, p. 1989, 1999
  42. Fat-free mass components in active vs sedentary females aged 55–75 yr
    Applied Radiation and Isotopes, vol. 49, no. 5-6, pp. 735–736, 1998
  43. Changes in body composition during adjuvant chemotherapy for breast cancer
    Applied Radiation and Isotopes, vol. 49, no. 5-6, pp. 637–638, 1998
  44. Assessment of body composition of children with cystic fibrosis (CF)
    Applied Radiation and Isotopes, vol. 49, no. 5-6, pp. 591–592, 1998
  45. Physics in Medicine and Biology, vol. 43, no. 9, pp. 2491–2501, 1998
  46. Theoretical treatment of human haemopoietic stem cell survival following irradiation by alpha particles
    International Journal of Radiation Biology, vol. 74, no. 1, pp. 111–118, 1998
  47. Is there a future for Neutron Capture Therapy?
    International Journal of Radiation Oncology*Biology*Physics, vol. 38, no. 4, p. 908, 1997
  48. Physics in Medicine and Biology, vol. 41, no. 11, pp. 2447–2462, 1996
  49. Physics in Medicine and Biology, vol. 40, no. 1, pp. 201–207, 1995
  50. Physics in Medicine and Biology, vol. 40, no. 10, pp. 1599–1608, 1995
  51. The influence of heavy water on boron requirements for neutron capture therapy
    Medical Physics, vol. 22, no. 5, p. 585, 1995
  52. MOSFET dosimeters: the role of encapsulation on dosimetric characteristics in mixed gamma-neutron and megavoltage X-ray fields
    IEEE Transactions on Nuclear Science, vol. 42, no. 6, pp. 1870–1877, 1995
  53. Physics in Medicine and Biology, vol. 39, no. 5, pp. 897–906, 1994
  54. Monte Carlo modelling of neutron depth dose distributions in optimizing prompt gamma in vivo neutron activation analysis systems
    Applied Radiation and Isotopes, vol. 45, no. 7, pp. 789–794, 1994
  55. Total body nitrogen as a predictor of clinical status in anorexia nervosa
    International Journal of Eating Disorders, vol. 15, no. 3, pp. 275–278, 1994
  56. Monte Carlo Calculations of Ion Passages Through Brain Endothelial Nuclei During Boron Neutron Capture Therapy
    International Journal of Radiation Biology, vol. 64, no. 6, pp. 739–747, 1993
  57. The Potential of Neutron Capture Therapy in the Management of Uncontrollable Localised Tumours
    Australasian Radiology, vol. 34, no. 4, pp. 297–305, 1990
  58. Neutron Capture Therapy Research in Australia
    Pigment Cell Research, vol. 2, no. 4, pp. 235–239, 1989
  59. Determination of the Concentration of Complex Boronated Compounds in Biological Tissues by Inductively Coupled Plasma Atomic Emission Spectrometry
    Pigment Cell Research, vol. 2, no. 4, pp. 281–285, 1989
  60. Neutron Irradiation of Human Melanoma Cells
    Pigment Cell Research, vol. 2, no. 4, pp. 319–324, 1989
  61. Induction of DNA Double-Strand Breaks by 157Gd Neutron Capture
    Pigment Cell Research, vol. 2, no. 4, pp. 330–332, 1989
  62. Morphological Changes in Human Melanoma Cells Following Irradiation With Thermal Neutrons
    Pigment Cell Research, vol. 2, no. 4, pp. 345–348, 1989
  63. Recommendations to the Japanese and Australian Governments for Future Research and Development of Melanoma Neutron Capture Therapy
    Pigment Cell Research, vol. 2, no. 4, pp. 379–384, 1989
  64. Constraints on the176Lu cosmochronometer
    Journal of Astrophysics and Astronomy, vol. 9, no. 1, pp. 7–15, 1988
  65. Determination of boron in biological tissues by inductively coupled plasma atomic emission spectrometry
    Analytical Chemistry, vol. 59, no. 17, pp. 2161–2164, 1987
  66. ACCUMULATION OF CHLORPROMAZINE AND THIOURACIL BY HUMAN MELANOMA CELLS IN CULTURE
    Australian Journal of Experimental Biology and Medical Science, vol. 64, no. 6, Article ID icb198656, 9 pages, 1986
  67. Journal of Physics G: Nuclear Physics, vol. 7, no. 9, pp. 1271–1284, 1981
  68. Journal of Physics G: Nuclear Physics, vol. 6, no. 3, pp. 381–391, 1980
  69. Journal of Physics G: Nuclear Physics, vol. 6, no. 9, pp. 1173–1188, 1980
  70. Valence neutron capture γ-ray spectrum in 54 Fe
    Physical Review C, vol. 22, no. 1, pp. 328–331, 1980
  71. Journal of Physics G: Nuclear Physics, vol. 4, no. 5, pp. 771–785, 1978
  72. Resonance and background interference in 54Fe neutron capture
    Physics Letters B, vol. 72, no. 3, pp. 323–325, 1978
  73. Odd-even effects in radiative neutron capture by 42Ca, 43Ca and 44Ca
    Nuclear Physics A, vol. 279, no. 2, pp. 317–332, 1977
  74. Non-statistical effects in neutron capture γ-ray spectra
    Nuclear Physics A, vol. 278, no. 2, pp. 204–216, 1977
  75. Valence neutron capture in 54Fe
    Nuclear Physics A, vol. 283, no. 1, pp. 37–44, 1977
  76. Resonant neutron capture in 40Ca
    Nuclear Physics A, vol. 259, no. 3, pp. 365–377, 1976
  77. keV Neutron capture cross sections of 134Ba and 136Ba
    Nuclear Physics A, vol. 256, no. 1, pp. 173–188, 1976
  78. Average neutron resonance parameters and radiative capture cross sectins for the isotopes of molybdenum
    Nuclear Physics A, vol. 270, no. 1, pp. 108–140, 1976
  79. Resonance neutron capture in silicon
    Nuclear Physics A, vol. 270, no. 1, pp. 164–174, 1976
  80. The neutron total and capture cross sections of 92, 94Zr
    Nuclear Physics A, vol. 269, no. 1, pp. 31–45, 1976
  81. Valence neutron capture in 88Sr☆
    Nuclear Physics A, vol. 269, no. 2, pp. 397–407, 1976
  82. Resonance neutron capture in 56Fe☆
    Nuclear Physics A, vol. 269, no. 2, pp. 408–428, 1976
  83. Neutron capture mechanism in 45Sc and 139La
    Physics Letters B, vol. 61, no. 2, pp. 161–163, 1976
  84. An investigation of d-wave neutron capture in the 40Ca(n, γ) reaction
    Physics Letters B, vol. 61, no. 5, pp. 441–443, 1976
  85. Neutron resonance capture in 138Ba
    Nuclear Physics A, vol. 252, no. 2, pp. 301–314, 1975
  86. Valence component in the neutron capture cross section of 90Zr
    Nuclear Physics A, vol. 246, no. 1, pp. 1–20, 1975
  87. The neutron capture cross section of natural silicon
    Nuclear Physics A, vol. 252, no. 1, pp. 62–76, 1975
  88. Neutron Resonance Parameters of ^{92}Mo
    Physical Review C, vol. 7, no. 4, pp. 1532–1541, 1973
  89. Comments on the Doorway State in ^{206}Pb
    Physical Review C, vol. 7, no. 6, pp. 2598–2600, 1973
  90. p-Wave Resonances in ^{111}Cd(n,γ)^{112}Cd
    Physical Review C, vol. 7, no. 2, pp. 780–787, 1973
  91. Neutron-Capture Cross Sections of the Stable Lead Isotopes
    Physical Review C, vol. 8, no. 4, pp. 1504–1517, 1973
  92. Thin 6Li(n, α)T transmission flux monitor☆
    Nuclear Instruments and Methods, vol. 96, no. 4, pp. 509–513, 1971
  93. Averaged resonance neutron capture in gold
    Physics Letters B, vol. 27, no. 8, pp. 494–496, 1968
  94. Neutron resonance measurements with a germanium detector
    Physics Letters B, vol. 27, no. 10, pp. 638–640, 1968
  95. keV neutron capture in nickel
    Nuclear Physics A, vol. 122, no. 1, pp. 220–233, 1968
  96. Averaged intensities of primary gamma rays after keV neutron capture in copper
    Nuclear Physics A, vol. 111, no. 1, pp. 1–11, 1968
  97. Response functions of a germanium-sodium iodide detector system
    Nuclear Instruments and Methods, vol. 53, pp. 61–70, 1967